Introduction
Endometrial cancer (EC) is now the second most prevalent cancer among women in the USA and one of the few cancers for which disease incidence is on the rise, particularly for aggressive histologic subtypes (1) (2) . Clinical management of EC includes total hysterectomy, bilateral salpingo-oopherectomy and pelvic and peri-aortic lymph node dissection and can be followed by adjuvant treatment with chemotherapy and vaginal brachytherapy. Given the increasing incidence and the paucity of effective treatments for advanced and recurrent EC, novel therapeutic agents that could be used alone or in combination with more traditional hormonal and cytotoxic chemotherapy to combat these trends are under active investigation. Emerging therapeutics for EC include the antihyperglycemic drug metformin (3) (4) (5) . Owing to its effect of inhibiting hepatic gluconeogenesis, metformin is widely used clinically to manage type II diabetes. Metformin activates adenosine monophosphate kinase (AMPK) that, in turn, stimulates a number of catabolic pathways, such as glucose uptake, glycolysis and fatty acid oxidation and inhibits numerous ATP-consuming processes, such as fatty acid, cholesterol and protein synthesis (3, 6) . In the context of cancer, metformin has been shown to dramatically decrease proliferation of a number of different human cancer cell lines in vitro (5, (7) (8) (9) . Metformin has also been shown to effectively repress tumor growth in xenograft models of breast, prostate and colon cancer (10) (11) (12) . In endometrial cancer cells, metformin-mediated AMPK activation decreases cell growth by inhibiting mTOR signaling (5) .
Epidemiologic studies of diabetic patients have revealed those treated with metformin exhibit a significantly reduced risk to develop diverse cancers relative to non-metformin treated patients (13) (14) . Focused meta-analyses have suggested that metformin improves disease outcome in diabetic cancer patients, as evidenced by a recent retrospective cohort study of 2,529 diabetic patients with early stage breast cancer that found that women receiving metformin and adjuvant chemotherapy had a higher complete pathologic response rate than those not taking metformin (15) . In endometrial cancer, our team recently completed a preoperative phase 0 window study investigating the impact of short-term metformin treatment in women undergoing surgical staging for type I endometrial cancer who were obese (BMI >30) and/or have diabetes, but who were metformin treatment naïve (ClinicalTrials.gov: NCT01911247). We recently reported a comparative metabolomic analysis of serum and tumor tissues before and after metformin treatment stratified by response as measured by decreased abundance of the proliferation antigen Ki-67 in tumor tissues as measured by IHC staining (4) . Metformin responders exhibited significantly decreased levels of phospho-AMPK as well as several downstream mTOR targets in tumor tissues and the serum metabolome reflected activated lipolysis suggesting activation of fatty acid metabolism following metformin treatment. We describe here a quantitative proteomics investigation of matched tumor tissues from the same cohort of pre-and postmetformin treated-patients collected during our phase 0 study of metformin in obese EC patients and identification of hematological and neurological expressed 1 (HN1) as a predictive and pharmacodynamic biomarker of metformin response in endometrial cancer patients.
Methods
Tissue Specimens: Formalin-fixed, paraffin embedded (FFPE) tissues were collected during pre-treatment biopsies or during primary surgery from endometrial cancer patients enrolled in a Phase 0 window trial for metformin treatment under IRB approved protocols (4). Thin (10 µm) tissue sections were cut using a microtome and placed on polyethylene naphthalate membrane slides. After staining with aqueous H&E, laser microdissection (LMD) was used to harvest tumor cells from the thin sections and were collected in 45 uL of LC-MS grade water (mean tumor cell area captured = ~16.1 ± 23 mm 2 ).
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) proteomics:
Tissue samples were processed and analyzed by high resolution LC-MS/MS on an Orbitrap Velos MS (Thermo Fisher, San Jose, CA) and HN1 IP samples (preparation described below) were similarly analyzed on a Fusion Lumos MS (Thermo Fisher) as previously described (16, 17) .
Peptide identifications were filtered to include peptide spectrum matches (PSMs) passing an FDR < 1.0%. Proteins included in subsequent quantitative analyses were required to have a minimum of two PSMs. Significantly altered proteins were identified using edgeR (18) based on PSMs normalized to the patient sample exhibiting the lowest total PSM counts (edgeR p<0.05).
Pathway analyses were performed using Ingenuity Pathway Analysis (Qiagen).
Immunohistochemistry (IHC)
Rabbit polyclonal anti-HN1 antibody was purchased from Atlas Antibodies (Sigma-Aldrich -HPA059729, Bromma, Sweden). IHC was carried out in the Bond Autostainer (Leica Microsystems Inc. Norwell MA). Briefly, slides were dewaxed in Bond Dewax solution (AR9222) and hydrated in Bond Wash solution (AR9590). Antigen retrieval was performed for with primary antibody (1:100) for 2 h. Antibody detection was performed using the Bond Polymer Refine detection system (DS9800). Stained slides were dehydrated and coverslipped.
Positive and negative controls (no primary antibody) were included during the run.
IHC image analysis
Stained slides were digitally scanned at 20x magnification using Aperio ScanScope-XT (Aperio Technologies, Vista, CA). Digital images were stored and analyzed within an Aperio were also harvested at 72 and 168 h after transfection to assess HN1 knockdown by immunoblotting and qPCR analyses. Two biological replicates were performed for each cell line.
Quantitative PCR
cDNA was prepared from equivalent amounts of total RNA by reverse-transcription using the Superscript VILO cDNA synthesis kit (Invitrogen). HN1 (Hs00602957_m1) and GAPDH (Hs99999905_m1) TAQMAN assays were obtained from Applied Biosystems (Thermo Fisher).
Quantitative PCR was performed using TAQMAN gene expression master mix of equivalent amounts of total cDNA for forty cycles (ABI GeneAmp 9700 DNA thermal cycler). Endpoint data was assembled by comparison of Delta-Ct values for HN1 versus corresponding GAPDH Delta-Ct values for each cell line. Triplicate technical replicates were performed.
Immunoblot analyses
Cells were washed with cold PBS and lysed in lysis buffer containing 1% SDS and 150 mM NaCl (pH 7.4). Equivalent amounts of protein lysates were resolved via 4-15% mini-PROTEIN TGX gels (Bio-Rad) and transferred to PVDF membranes. Membranes were blocked for 1 hr using 5% non-fat dry milk (Bio-Rad) and incubated with primary antibody overnight at 4 °C, secondary antibody for 3 h at ambient temperature, and SuperSignal West Chemiluminescent Substrate (Thermo Scientific) for 5 min. Images were acquired using a ChemiDoc XRS+ system (Bio-Rad). Anti-Ki67 and anti-GAPDH were purchased from Abcam. Anti-MYC was purchased from Santa Cruz. Anti-HN1 was purchased from GeneTex. Anti-pAMPKα Thr172, anti-AMPKα, anti-pAKT1 Ser473, anti-AKT (pan) and goat anti-rabbit IgG HRP-linked were purchased from Cell Signaling Technologies.
IP-MS analyses of the HN1
Twenty million RL95-2 cells were used per immunoprecipitation. For each immunoprecipitation, 30 µL of protein G sepharose 4 fast flow (GE Healthcare) was bound to 5 µL of anti-HN1 (GeneTex) for 2.5 h at 4⁰C with end-over-end rotation. Cells were lysed in 50 mM Tris (pH 7.4), 137 mM NaCL, 10% glycerol and 0.1% Triton X supplemented with 1 X Halt protease and phosphatase inhibitor (ThermoFisher Scientific) and 5mM EDTA for thirty min on ice. Lysate was spun at 16,000 x g for 20min at 4 ⁰C and the supernatant was incubated with protein G sepharose 4 fast flow and anti-HN1 for 3 h at 4⁰C with end-over-end rotation. Sample was resolved on a 4-15% mini-PROTEAN TGX gel (Bio-Rad) and ten gel bands per lane were cut.
Gel bands were digested using trypsin/LysC Mix (Promega) overnight and samples were cleaned up using Reversed-Phase ZipTip (Millipore) according to manufacturer's protocol prior to LC-MS/MS analysis. Immunoprecipitation with anti-HN1 with protein G sepharose 4 fast flow was performed in duplicate. Immunoprecipitation with protein G sepharose 4 fast flow alone was used as a control.
Public-Data Analysis:
Normalized RNA-seq data (TCGA V2, (20) for HN1 and Ki-67 was downloaded from the https://gdac.broadinstritute.org for n=542 EC patients and transcript abundance was directly compared by Spearman correlation. Clinical characteristics were extracted from cgdsr (version 1.2.5) and a Kaplan-Meier analysis with log-rank testing was performed to assess the relationship between HN1 abundance and patient outcome using survival (version 2.37-7) package in R (version 3.1.2). For Kaplan-Meier curves, high versus low transcript expression was defined by the median cut-point capped at 60 months.
Results

Proteomic analysis of endometrial cancer (EEC) tumor tissues collected from pre and posttreated patient reveals conserved protein alterations between metformin responders and non-responders.
Tumor tissues from endometrial cancer patients in a pre-operative phase 0 window trial were stratified as responders (n=13) or non-responders (n=7) to metformin treatment (Table 1) .
Response was defined as a decrease in IHC staining for Ki-67 when comparing pre-versus posttreatment endometrial cancer tissue as previously described (4) . Quantitative LC-MS/MS-based global proteomic analyses of pathologically-defined, tumor cell populations harvested by laser microdissection from FFPE endometrial biopsies and endometrial cancer surgical tumor tissues identified 1,289 proteins by at least two peptide spectral matches (PSMs) across patients (Supplemental Table 1 and 2). Seventy-nine proteins were identified to be significantly altered (edgeR p-value ≤ 0.05) in pre-treatment tumor cells from metformin responder and nonresponder patients ( Figure 1 and Supplemental Table 3 ). Pathway analysis revealed top altered pathways to include adenosine monophosphate kinase (AMPK) signaling (Table 2, Supplemental   Table 4A ), along with those related to activating cellular signaling, regulating cellular proliferation, and inhibiting cell death and apoptosis in tissues in metformin responders (Table 2,   Supplemental Table 4B ). Protein alterations in pre-treatment tissues from responder versus nonresponder patients (Supplemental Table 5A ) were correlated with significant alterations in post versus pre-treated tissues from metformin responders (edgeR p-value ≤ 0.05), revealing 11 coaltered proteins between these groups (Uniprot Accession * and bolded, Supplemental Table   5A ). Further analyses of metformin responders revealed activation of cell death and apoptosis signaling, but inhibition of viral infection as well as molecular transport in response to metformin (Supplemental Table 5B ). Additional analyses of significant protein alterations in metformin non-responders (Supplemental Table 6A ) also revealed activation of cell death as well as organ hypoplasia signaling, inhibition of T cell proliferation and leukocyte viability signaling in post versus pre-metformin treated tissues (Supplemental Table 6B ). Figure 5A , 5B, 5D and 5E). These analyses revealed that loss of HN1 expression did not alter the response of EC cells to metformin treatment ( Figure 5C and 5F). As AKT has previously been noted to be hyperactivated in low HN1 backgrounds (21), we further assessed activation of AKT in HN1 silenced cells. However, we did not observe alterations of p-AKT (S473) abundance in EC cells transfected with HN1-specific versus non-targeting siRNAs ( Figure 5A and 5D) . Further, recent evidence has shown that HN1 knockdown results in decreased abundance of the MYC oncogene (22) . We further assessed MYC abundance in HN1 silenced endometrial cancer cells, but did not reproduce this finding ( Figure 5A and 5D ). We further assessed the impact of silencing HN1 on the proliferation rate of RL95-2 and ACI-181 cells ( Figure 6 ). These analyses revealed that loss of HN1 expression does not significantly alter the proliferation of endometrial cancer cells.
Hematological and Neurological Expressed 1 (HN1) is correlated with Ki-67 expression and
associated with altered overall survival in endometrial cancer patients. As Ki-67 and HN1 abundance were both decreased following metformin treatment, we assessed correlation trends of HN1 protein abundance (Supplemental Table 7 ) relative to Ki-67 protein abundance previously assessed in these tissues (4). We found that HN1 and Ki-67 exhibit concordant abundance trends in comparisons of both pre-(Spearman = 0.44) as well as in post-(Spearman=0.58) metformin treated tissues. We further assessed correlation of HN1 and Ki-67 transcript expression using a public RNA-seq dataset established from n=542 endometrial cancer patient tumor tissues (20) and found that these genes were positively correlated in endometrial cancer patient tissues (Spearman = 0.37, Supplemental Figure 1A ). We also assessed whether HN1 abundance was directly correlated with disease outcome in endometrial cancer patients and found that elevated expression of HN1 was associated with poor overall survival (n=540 EC patients, Log-rank pvalue = 0.047, Supplemental Figure 1B) but not with disease-free survival (n=499 EC patients, Log-Rank p-value = 0.14, data not shown).
Hematological and Neurological Expressed 1 (HN1) exhibits binding partners regulating metabolic signaling pathways in endometrial cancer cells. We performed an immunoprecipitation and mass spectrometry (IP-MS)-based analyses of HN1 in subconfluent
RL95-2 cells to identify putative binding partners of HN1 (Supplemental Table 8A ). HN1 was the most abundantly identified protein in HN1 IP-MS biological replicates analyses, i.e. 61 ± 8
PSMs, following removal of proteins identified in a companion control IP-MS analyses of sepharose beads alone that contained no anti-HN1 antibody. Top functional pathways enriched following analyses of proteins abundantly identified with HN1, i.e. ≥ 10 PSMs in both HN1 IP-MS analyses (designated with * in Supplemental Table 8A ) were associated with metabolic pathways such as purine nucleotides de novo biosynthesis, glycolysis and gluconeogenesis as well as fatty acid biosynthesis signaling (Supplemental Table 8B ).
Conclusions:
The current study sought to identify proteomic alterations in tumor tissues harvested from endometrial cancer patients before and after daily treatment with metformin (850mg) for 4 weeks prior to surgical staging. Women who responded to metformin exhibited a significant decrease (7 to 50%) in expression of the cellular proliferation marker Ki-67 in post-treated tumor tissues, whereas non-responders exhibited a slight increase in Ki-67 IHC staining (~2-12%), as described previously (4) . A global quantitative LC-MS/MS-based proteomics analysis identified discrete protein alterations in tumor cells harvested by LMD from pre-treated endometrial biopsies that correlate with canonical cellular pathways that include AMPK signaling, a kinase regulating cellular energy homeostasis activated by metformin (6), as well as pathways involved in activating cellular proliferation and inhibiting cell death signaling in metformin responders.
Among the proteins altered, Hematological and Neurological Expressed 1 (HN1) was the most significantly elevated protein in pre-treated endometrial biopsies from metformin responders (responder versus non-responder logFC=3.42, edgeR p-value = 9.78E-06). We cross-correlated HN1 in pre and post-treatment biopsies in metformin responders and found that HN1 was also significantly decreased following metformin treatment (post-versus pre-treatment logFC = -1.06, edgeR p-value = 0.02) -a finding that was independently verified by IHC.
Hematological and Neurological Expressed 1 (HN1), also known as Jupiter microtubule associated homolog 1 (JPT1), is a ~16 kDa protein (Q9UK76, uniprot.org) initially identified as an abundant transcript in both murine hematopoietic and brain cells (23) . As HN1 was significantly elevated in patients who responded to metformin, we assessed the impact of silencing HN1 expression on response to metformin using two endometrial cancer cell line models, i.e. RL95-2 and ACI-181 ( Figure 5 ). We found that loss of HN1 did not alter cellular response to metformin treatment in vitro. In cancer, HN1 has been shown to inhibit the growth of androgen-sensitive, but promote the growth of androgen-insensitive, prostate cancer cells through altered androgen receptor stability and by modulating cell metabolism and cell cycle progression through protein kinase B (AKT) and downstream glycogen synthase kinase-3 beta (GSK3β)/ β-catenin (CTNNB1)-dependent mechanisms (21, 24) . Specifically, silencing of HN1 expression increased activation of AKT via upregulation of p-AKT (S473) in androgendependent and independent prostate cancer cell lines (21) . We similarly assessed modulation of p-AKT (S473) following knockdown of HN1 in endometrial cancer cell lines, though we did not reproduce this finding (Figure 4 ). Recent evidence has also shown that elevated HN1 expression is directly correlated with poor prognosis in breast cancer patients (22) . Further investigations revealed that HN1 increases the migratory and invasive potential of breast cancer cells by upregulating the MYC oncogene and downstream effectors in vitro and further increases breast tumorigenesis in vivo (22) . We, however did not see any alterations in MYC protein abundance following silencing of HN1 in endometrial cancer cells ( Figure 5 ). We found that metformin treatment inhibited endometrial cancer cell proliferation in vitro, as evidence by decreased Ki-67 levels, and that this response was further accompanied by loss of HN1 abundance ( Figure 5 ).
Pathway analyses of significantly altered proteins in metformin pre-treatment tumors from responders revealed that cellular proliferation signaling was altered in metformin responders as evidenced by elevation of proliferating cell nuclear antigen in responder patients (PCNA, edgeR LogFC=1.29, p-value = 0.025). PCNA regulates DNA replication via interactions with DNA polymerase delta and is a marker of cellular proliferation often assessed during routine histopathology analyses of tumor tissues along with Ki-67 to determine the proliferative indices of tumor cells in situ (25) . Indeed, we previously observed (4) that pre-treatment tumor tissues from metformin responders exhibited elevated Ki-67 expression levels versus non-responders (47.3% vs. 24.9%, p-value = 0.004), providing suggestive evidence that these patients may harbor tumor cells with a greater proliferative capacity. That we do not observe an association between HN1 and response to metformin and as HN1 levels closely parallel PCNA levels in responders versus non-responders, HN1 abundance may also serve as a surrogate measure of proliferative activity in endometrial cancer cells. Similarly to our findings with HN1, recent assessments of Ki-67 have identified that this hallmark biomarker of cellular proliferation does not directly contribute to tumor cell proliferation (26, 27 ), but rather functions to maintain cancer stem cell populations (27) and facilitates chromosomal motility and mitotic spindle interactions (28) . To gain further insight into the possible biologic roles of HN1 in endometrial cancer cells, we performed an immunoprecipitation-mass spectrometry based analyses of HN1 in subconfluent RL95-2 cells to identify functional binding partner candidates. These analyses revealed putative HN1 binding proteins to be predominantly associated with metabolic signaling pathways such as nucleotide and aerobic glycolysis and fatty acid signaling. Future studies will be focused on validating these HN1 binding partner candidates and elucidating the roles of these targets along with HN1 in the regulation of metabolic signaling pathways as they pertain to metformin treatment.
Immunohistochemical markers of metformin response used in clinical trials to date include assessments of AMPK abundance and activation state (p-AMPK, T172), mTOR signaling, such as p-S6 kinase as well as p-EIF4-BP1, as well as assessing markers of cellular proliferation (29) .
Indeed, we observe activation of AMPK via increased levels of p-AMPK (T172) in endometrial cancer cells treated with metformin in vitro (Figure 4) . We did not, however, observe elevated p-AMPK (T172) by IHC in endometrial cancer tissues following metformin treatment (4), though Ki-67 was clearly altered these same tissues, recapitulating our findings in vitro. Comparative analyses of Ki-67 and HN1 protein abundance by IHC analyses in pre and post-metformin treated patient tissues revealed these protein abundances to be positively correlated. We assessed the correlation of HN1 and Ki-67 mRNA abundance in public data for over 500 endometrial cancer patients and found that HN1 and Ki-67 expression are positively correlated (R=~0.365).
Furthermore, we also identified that elevated HN1 is associated with poor overall survival, underscoring that high HN1 expressing patients may experience a survival benefit from metformin treatment. With further validation, these data suggest that IHC assessment of HN1 in pre-surgical endometrial tissue biopsies may aid to prioritize patients for neoadjuvant treatment with metformin, and that this protein may further function as a pharmacodynamic surrogate of therapeutic response. Future studies will focus on validating the performance of HN1 as a pharmacodynamic biomarker of metformin response in an expanded cohort of endometrial cancer patients that will include both obese and non-obese patients.
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